Pandemic workforce trends continue to create challenges for pharma.
*** Time and Date: Tuesday, November 17 I 11:00 am – 2:30 pm EST *** *** On-demand available after final airing until Nov. 17, 2021***
With a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.
Delivering value with enterprise program management.
As healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.
COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
How pharma companies can make justice and integrity a priority.
Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.
Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Off-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system's rejection and navigating the FDA's approval process are crucial challenges.
Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
Owning a self-service data platform allows emerging pharma and biotech companies to accelerate past data engineering intricacies and focus on ad-hoc analytics to discern how their data can help them meet objectives for clinical operations, medical affairs, and commercial teams.
Recent events can provide digital therapeutics companies with clear lessons for the future.
Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.
How to cultivate trust & connections in life sciences in a time of AI bias.
Biopharma has a responsibility to meet patients where they are.
To successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Commercial Health Insurance may bring more opportunities for market access in China.
How pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.
With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.